Dr. Reddy’s Laboratories has launched its authorized generic version of Par Pharmaceutical’s VASOSTRICT (vasopressin injection, USP) Vials in the U.S. Market approved by the U.S. Food and Drug Administration (USFDA).
The VASOSTRICT brand market had U.S. sales of approximately $878.5 million MAT for the most recent twelve months ending in December 2021 according to IQVIA Health. Dr. Reddy’s Vasopressin Injection, USP, is supplied in a carton of 25 single-dose vials each containing vasopressin 1 mL at 20 units/mL.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
